Microfluidic-assisted nanoparticle fabrication represents a paradigm shift in the design and clinical translation of targeted therapies for liver cancer. By allowing real-time control over nanoparticle synthesis and enabling combination delivery strategies, this approach holds great promise for personalized and precision oncology. Continued integration of microfluidic engineering with biomaterial science and clinical insights is expected to accelerate the realization of safe, reproducible, and patient-tailored nanotherapeutics for hepatocellular carcinoma.